Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response & Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)

NCT02010203 is registered in ClinicalTrials.gov with Heat Biologics as lead sponsor.

NCT NCT02010203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02010203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response & Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)
Lead sponsor
Heat Biologics
Phase
Phase 1/2
Overall status
Terminated
Start date
December 31, 2013
Completion date
April 30, 2018
Enrollment
104 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer